Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) — $8 million — ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment.

Verquvo and Entresto are both prescription drugs used to help prevent complications of heart failure. Verquvo is taken once per day. Entresto is taken twice per day. Various factors could affect ...

The first line of pharmacological treatment for schizophrenia is antipsychotic medication. However, antipsychotic medications are ineffective in more than 30% of people with the disorder. This is ...

In jails and prisons, drugs are still available, effective treatment is rare, and overdoses occur. People can also cycle in and out of jail, ending up back on the street without meaningful care or ...

Novartis AG is fighting MSN Laboratories Pvt. Ltd.'s efforts to pull a revived patent from Entresto’s entry in the FDA’s Orange Book, urging a Delaware federal judge to toss the generic-drug maker’s ...

False Belief 1: Drug experimentation is normal for teens and shouldn’t alarm parents. Drug use and experimentation among teens often is ignored by many—even parents, who then may be unaware ...

However, a doctor will address any underlying causes and may prescribe medications such as furosemide or heparin to reduce fluids in the body. Edema is swelling due to liquid trapped in the body ...

Readers will recall that the Centers for Medicare and Medicaid Services announced Novartis' Entresto as one of the first 10 medicines in the Medicare Drug Price Negotiation Program for 2026.